Lexicon Pharmaceuticals Inc to Provide Update on Sotagliflozin Program from EASD Conference Call
Llamada en conferencia Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc Conference call or earnings call will be held on 13-sep-2017 During the earnings conference call's session Lexicon Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Lexicon Pharmaceuticals Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development of breakthrough treatments for human disease. We have advanced multiple drug candidates into clinical development and are presently devoting most of our resources to the development of our two most advanced drug candidates: * We are developing telotristat etiprate, or LX1032, an orally-delivered small molecule drug candidate, as a treatment for carcinoid syndrome. We have reported positive top-line data from both our pivotal TELESTAR Phase 3 clinical trial and its companion TELECAST Phase 3 clinical trial of telotristat etiprate in carcinoid syndrome patients. We are presently preparing an application for regulatory approval to market telotristat etiprate in the United States and, if approved, for the commercial launch of telotristat etiprate in the United States.Leer más Llamada en conferencia